HK30283A - An immune gammaglobulin preparation for the treatment of rheumatoid arthritis - Google Patents

An immune gammaglobulin preparation for the treatment of rheumatoid arthritis

Info

Publication number
HK30283A
HK30283A HK302/83A HK30283A HK30283A HK 30283 A HK30283 A HK 30283A HK 302/83 A HK302/83 A HK 302/83A HK 30283 A HK30283 A HK 30283A HK 30283 A HK30283 A HK 30283A
Authority
HK
Hong Kong
Prior art keywords
preparation
treatment
gammaglobulin
immune
rheumatoid arthritis
Prior art date
Application number
HK302/83A
Other languages
English (en)
Inventor
Ralph J Stolle
Original Assignee
Stolle Research And Development Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Research And Development Corporation filed Critical Stolle Research And Development Corporation
Publication of HK30283A publication Critical patent/HK30283A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK302/83A 1978-02-06 1983-08-25 An immune gammaglobulin preparation for the treatment of rheumatoid arthritis HK30283A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87514078A 1978-02-06 1978-02-06

Publications (1)

Publication Number Publication Date
HK30283A true HK30283A (en) 1983-09-02

Family

ID=25365266

Family Applications (1)

Application Number Title Priority Date Filing Date
HK302/83A HK30283A (en) 1978-02-06 1983-08-25 An immune gammaglobulin preparation for the treatment of rheumatoid arthritis

Country Status (10)

Country Link
JP (1) JPS54113425A (enrdf_load_stackoverflow)
CH (1) CH651210A5 (enrdf_load_stackoverflow)
DE (1) DE2904044C2 (enrdf_load_stackoverflow)
DK (1) DK158138C (enrdf_load_stackoverflow)
FR (1) FR2416015A1 (enrdf_load_stackoverflow)
GB (1) GB2013691B (enrdf_load_stackoverflow)
HK (1) HK30283A (enrdf_load_stackoverflow)
IT (1) IT1116524B (enrdf_load_stackoverflow)
NL (1) NL7900766A (enrdf_load_stackoverflow)
SE (1) SE448344B (enrdf_load_stackoverflow)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732757A (en) * 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
DE3264713D1 (en) * 1981-02-26 1985-08-22 Unilever Plc A process and apparatus for the recovery of immunoglobulines
EP0064103B1 (en) * 1981-04-28 1985-11-06 The Stolle Research And Development Corporation Method of obtaining an anti-inflammatory bovine milk
JP2561234B2 (ja) * 1981-05-12 1996-12-04 スト−ル・リサ−チ・アンド・デイベロップメント・コ−ポレ−ション 抗炎症剤
JPS58154513A (ja) * 1982-03-09 1983-09-14 Sendai Biseibutsu Kenkyusho 予防及び治療薬
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
EP0127712B1 (en) * 1983-06-07 1989-01-11 The Stolle Research And Development Corporation Deodorant containing bacterial antibodies
JPS6112629A (ja) * 1984-06-28 1986-01-21 Lion Corp 口腔内組成物
DE3785033T2 (de) * 1987-07-21 1993-10-07 Stolle Res & Dev Verfahren zum Erhalten von immunregulierenden Faktoren mittels Säugetierimmunisierung.
JP2664906B2 (ja) * 1987-08-13 1997-10-22 ストール・リサーチ・アンド・デイベロップメント・コーポレーション 改良された哺乳類の免疫法
WO2000062806A1 (en) * 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
JP2004525077A (ja) * 2000-09-28 2004-08-19 リサーチ　コーポレイション　テクノロジーズ，インコーポレイテッド イムノグロブリンｇ強化血漿画分の経口投与による免疫媒介性疾病の治療
US20040202660A1 (en) * 2001-01-30 2004-10-14 Joy Campbell Methods and compositions for treatment of immune dysfunction disorders
EP1357943A2 (en) * 2001-01-30 2003-11-05 The Lauridsen Group Incorporated Methods and compositions for modulating the immune system of animals
JP4960632B2 (ja) * 2006-01-10 2012-06-27 学校法人北里研究所 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物
JP5361132B2 (ja) * 2006-03-10 2013-12-04 国立大学法人信州大学 免疫グロブリンｇを含有する経口用免疫調節剤、その製造方法及び経口用免疫調節剤を配合してなる飲食品
JP2008179572A (ja) * 2007-01-25 2008-08-07 Shinshu Univ 免疫グロブリンＦｃフラグメントレセプタータンパク及び／又は免疫グロブリンＦｃフラグメントレセプター様タンパク産生抑制剤及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617538C3 (de) * 1965-10-24 1979-10-04 The Immune Milk Co. Of America, Inc., Cincinnati, Ohio (V.St.A.) Verfahren zur Herstellung von Tetanus-Antitoxin
DE1617769A1 (de) * 1967-06-10 1971-04-01 Rehm Eberhard Verfahren zur Gewinnung von spezifischen Antikoerper enthaltender Milch und daraus hergestellter Praeparate
JPS5136326A (ja) * 1974-09-24 1976-03-27 Komatsu Seiren Co Seikeigorufubooru
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS521014A (en) * 1975-06-17 1977-01-06 Stolle Res & Dev Pharmaceutically acceptable carrier containing milk immunoglobulin
JPS5381613A (en) * 1976-12-28 1978-07-19 Green Cross Corp:The Remedies for enteral infection diseases
CH627079A5 (en) * 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin

Also Published As

Publication number Publication date
IT7947888A0 (it) 1979-02-05
GB2013691A (en) 1979-08-15
SE448344B (sv) 1987-02-16
FR2416015B1 (enrdf_load_stackoverflow) 1983-06-17
JPS54113425A (en) 1979-09-05
DE2904044A1 (de) 1979-08-30
GB2013691B (en) 1982-08-18
IT1116524B (it) 1986-02-10
CH651210A5 (de) 1985-09-13
DK49479A (da) 1979-08-07
JPH0160455B2 (enrdf_load_stackoverflow) 1989-12-22
FR2416015A1 (fr) 1979-08-31
DK158138C (da) 1990-08-27
DK158138B (da) 1990-04-02
SE7900798L (sv) 1979-08-07
DE2904044C2 (de) 1986-02-06
NL7900766A (nl) 1979-08-08

Similar Documents

Publication Publication Date Title
HK30283A (en) An immune gammaglobulin preparation for the treatment of rheumatoid arthritis
Mietens et al. Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins
US4748018A (en) Method of passive immunization of mammals using avian antibody
US4341763A (en) Methods of vaccinating humans against rotavirus infection
EP0077734A3 (en) Production of monoclonal antibodies against bacterial adhesins
EP0143445A3 (en) Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
EP0046909B1 (en) Pharmaceutical composition
CA2022420A1 (en) Escherichia coli vaccine
Tomita et al. A comparison of two commercially available Escherichia coli J5 vaccines against E. coli intramammary challenge
IE940698L (en) Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
Boesman-Finkelstein et al. Bovine lactogenic immunity against cholera toxin-related enterotoxins and Vibrio cholerae outer membranes
DK398683A (da) Fremgangsmaade til fremstilling af antistoffer
Cantey Prevention of bacterial infections of mucosal surfaces by immune secretory IgA
EP0914831A3 (en) Biological product for preventive or therapeutic oral administration against canine parvovirosis
Hanson et al. Different secretory IgA antibody responses after immunization with inactivated and live poliovirus vaccines
NZ299579A (en) ue of hyperimmune milk to restore decreasing physiologic function
DE69823638D1 (de) Oralprodukt zur Prävention und Behandlung von ansteckender Gastroenteritis in Kälbern
Iizumi et al. Augmentation of Helicobacter pylori urease activity by its specific IgG antibody: implications for bacterial colonization enhancement
Westerink et al. The thymus-dependent nature of the murine antibody response to a monoclonal anti-idiotypic antibody to the Neisseria meningitidis serogroup C capsular polysaccharide
Nathanson et al. Cyclophosphamide-induced immunosuppression demonstrated in Pasteurella multocida-vaccinated chickens
NO771289L (no) Middel til profylaks og terapi av gastro-enteritis
Kaijser Peroral Immunization of Healthy Adults with Live Escherichia coli O4K12 Bacteria: Antibody Response as Measured in Serum and Secretions
RU2090193C1 (ru) Способ получения специфического лактоглобулина
Jertborn Immune response in humans after oral cholera vaccination.
Odendaal et al. The passive protection of lambs against Clostridium perfringens type D with semi-purified hyperimmune serum

Legal Events

Date Code Title Description
PE Patent expired